ADPT vs TEM Stock Comparison

Adaptive Biotechnologies and Tempus AI Prices as of Nov 13, 2026 Peers: Industry group
TEM Tempus AI, Inc.
$71.60 +4.8% 1M +5.4% 1Y
Market cap
$11.84B
P/E
–
Revenue (TTM)
$1.51B
Div. yield
–
Diagnostic Labs Healthcare
3 wins

Head to Head

6 decided of 12

Tempus AI leads on 3 of the 12 questions below (Tempus AI 3, Adaptive Biotechnologies 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionADPTTEMLeader
Larger companyMarket capitalisation $4.50B $11.84B TEM
Cheaper on earningsLower P/E, profitable companies only -63.8x -62.6x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — — –
Faster revenue growthRevenue growth, trailing twelve months +17.9% +36.6% TEM
More profitableNet margin, trailing twelve months -23.7% -12.5% TEM
Better return on capitalReturn on invested capital — -57.2% –
Less leveragedLower net debt / EBITDA — — –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +105.4% +5.4% ADPT
Better 5-year returnAnnualised price return, 5 years -2.6%/yr — –
Less volatileAnnualised volatility, 1 year 67.6% 77.8% ADPT
Higher overall scoreMean of the five percentile scores vs peers 42/100 37/100 ADPT

Percentile Scorecard

ADPTTEM

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisADPTTEM
Valuation 12 #87 of 99 11 #88 of 99
Growth 83 #16 of 89 61 #35 of 89
Profitability 25 #69 of 92 19 #75 of 92
Financial Health 70 #32 of 103 56 #46 of 103
Shareholder Returns 21 #50 of 63 –
Overall 42 37
  • ADPT ranked among 103 companies in Healthcare Providers
  • TEM ranked among 103 companies in Healthcare Providers

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodADPTTEMSPY
1 month +13.3%+4.8% -2.0%
3 months +17.4%+37.4% -2.8%
6 months +126.3%+63.0% +2.0%
Year to date +78.8%+21.3% +10.6%
1 year +105.4%+5.4% +12.2%
3 years +610.0%— +68.1%
3 years, per year +92.3%— +18.9%
5 years -12.6%— +61.4%
5 years, per year -2.6%— +10.1%

Risk

MeasureADPTTEMSPY
Volatility, 1Y 67.6%77.8% 13.6%
Downside volatility, 1Y 62.9%66.1% 13.9%
Beta vs S&P 500, 1Y 1.572.41 1.00
Return / volatility, 1Y 1.560.07 0.90
Max drawdown, 5Y -92.8%-59.8% -25.4%
From 52-week high -4.0%-15.8% -3.2%
52-week high $30.26$85.08 $779.14
52-week low $12.41$41.55 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleADPTTEM
P/E now vs peer median -66.0xmedian 22.4x -68.6xmedian 22.4x
P/S now vs peer median 15.7xmedian 1.3x 8.4xmedian 1.3x
EV/EBITDA now vs peer median -132.7xmedian 14.2x -131.1xmedian 14.2x
P/FCF now vs peer median -531.8xmedian 19.0x -92.7xmedian 19.0x
P/B now vs peer median 25.5xmedian 2.6x 25.4xmedian 2.6x
PEG now vs peer median -1.90median 0.84 —median 0.84

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsADPTTEM
Revenue $298.01M $1.51B
Gross profit $220.98M $972.95M
Operating income -$48.21M -$278.90M
Net income -$70.73M -$189.29M
Free cash flow -$8.82M -$136.79M
R&D $83.18M $197.35M
EPS (diluted) $-0.38 $-1.04
Cash & equivalents $75.62M $590.48M
Shares (diluted) 186.88M 181.31M
Enterprise value $3.41B $9.00B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricADPTTEM
P/E -66.0x -68.6x
P/FCF -531.8x -92.7x
P/Operating cash flow -1,097x -117.1x
P/S 15.7x 8.4x
P/B 25.5x 25.4x
P/Tangible book 25.6x 61.4x
EV/EBITDA -132.7x -131.1x
EV/EBIT -91.1x -43.2x
EV/Revenue 14.7x 8.0x
EV/FCF -498.0x -88.1x
EV/Operating cash flow -1,027x -111.2x
PEG (3Y EPS CAGR) -1.90 –

Growth

14 metrics
MetricADPTTEM
Revenue growth (1Y) 17.9% 36.6%
Revenue CAGR (3Y) 18.4% –
Gross profit growth (1Y) 21.7% 42.6%
Gross profit CAGR (3Y) 27.3% –
Operating income growth (1Y) 38.3% -15.2%
Operating income CAGR (3Y) 37.3% –
Net income growth (1Y) 11.1% 7.2%
Net income CAGR (3Y) 28.8% –
EPS growth (1Y) 22.7% 10.4%
EPS CAGR (3Y) 34.7% –
Operating cash flow growth (1Y) 92.9% 50.9%
Operating cash flow CAGR (3Y) 70.1% –
Free cash flow growth (1Y) 86.0% 44.1%
Free cash flow CAGR (3Y) 62.8% –

Profitability

14 metrics
MetricADPTTEM
Gross margin 74.2% 64.5%
EBITDA margin -11.1% -6.1%
Operating margin -16.2% -18.5%
Pretax margin 5.1% -12.2%
Net margin -23.7% -12.5%
FCF margin -3.0% -9.1%
Operating cash flow margin -1.4% -7.2%
Return on equity -42.3% -40.4%
Return on assets -10.7% -7.9%
Return on invested capital – -57.2%
Return on capital employed -8.6% -14.1%
Asset turnover 0.5x 0.6x
Cash conversion (OCF / net income) 0.1x 0.6x
Stock comp / revenue 15.5% 13.3%

Financial Health

11 metrics
MetricADPTTEM
Debt / assets – –
Debt / equity – –
Net debt / EBITDA – –
Debt / FCF – –
Liabilities / assets 73.1% 79.6%
Equity / assets 26.9% 20.4%
Interest coverage -5.3x -6.0x
Current ratio 4.0x 2.6x
Quick ratio 3.7x 2.4x
Cash ratio 3.0x 1.5x
Altman Z-score 3.45 3.04

Shareholder Returns

7 metrics
MetricADPTTEM
Dividend yield – –
Net buyback yield -0.9% –
Shareholder yield -0.9% 0.0%
Payout ratio (earnings) – –
Payout ratio (FCF) – –
Dividend growth (1Y) – –
Dividend CAGR (3Y) – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusADPTTEM
EPS, next fiscal year $-0.42FY2026 $-0.05FY2026
Revenue, next fiscal year $297.43MFY2026 $1.64BFY2026
Revenue growth, next FY +7.4%FY2026 +29.0%FY2026
Revenue growth, the year after +32.5% +25.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersADPTTEM
Held by institutions 97.2% 63.0%
Institutions holding 301 486
Change in shares held, QoQ +2.5% +5.0%
Institutions buying 160 285
Institutions selling 87 119
Buyers to sellers 1.84 2.39

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ADPTTEM
ADPT 1.00 0.55
TEM 0.55 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ADPT and TEM?

Tempus AI (TEM) is the largest by market capitalisation: Adaptive Biotechnologies (ADPT) $4.50B, Tempus AI (TEM) $11.84B.

Which company is growing faster?

Tempus AI (TEM) grew revenue fastest over the trailing twelve months: Adaptive Biotechnologies (ADPT) +17.9%, Tempus AI (TEM) +36.6%.

Which company is more profitable?

Tempus AI (TEM) has the highest net margin (Adaptive Biotechnologies (ADPT) -23.7%, Tempus AI (TEM) -12.5%).

Which stock has performed better?

Over the past year Adaptive Biotechnologies (ADPT) returned the most: Adaptive Biotechnologies (ADPT) +105.4%, Tempus AI (TEM) +5.4%. Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Adaptive Biotechnologies (ADPT) has been the steadiest (Adaptive Biotechnologies (ADPT) 67.6%, Tempus AI (TEM) 77.8%). Volatility measures how widely the price swings, not the risk of the business.

Do ADPT and TEM move together?

Their daily returns over the past year have a correlation of 0.55, a moderate positive relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, ADPT and TEM?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Tempus AI (TEM) leads on 3. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.